In vivo studies have also shown that B02 greatly improves the therapeutic efficacy of cisplatin on tumor cells, further supporting the potential of RAD51-specific small molecule inhibitors as a viable approach for combination anti-cancer therapy [213]. The gene discussed is RAD51; the disease is neoplasm.